Back to top
more

Masimo (MASI)

(Delayed Data from NSDQ)

$140.43 USD

140.43
1,106,202

-2.57 (-1.80%)

Updated Sep 19, 2025 04:00 PM ET

After-Market: $140.34 -0.09 (-0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (92 out of 245)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here's Why You Should Retain Masimo (MASI) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Masimo (MASI) owing to its focus on patient monitoring.

Zacks Equity Research

Masimo's (MASI) SedLine Receives FDA's Pediatric Indication

by Zacks Equity Research

The latest FDA clearance for Masimo's (MASI) SedLine is likely to improve brain function monitoring in pediatric patients.

Zacks Equity Research

Masimo's (MASI) Q4 Earnings Surpass Estimates, Margins Up

by Zacks Equity Research

Masimo's (MASI) robust product shipments, along with strong sensor sales, drive its Q4 sales.

Zacks Equity Research

Masimo (MASI) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Masimo (MASI) delivered earnings and revenue surprises of 10% and 2.63%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Masimo (MASI) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Masimo (MASI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Masimo (MASI) Stock Jumps 6%: Will It Continue to Soar?

by Zacks Equity Research

Masimo (MASI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Allscripts (MDRX) Reports Solid Preliminary Q4 Revenues

by Zacks Equity Research

Allscripts' (MDRX) revenue growth in the fourth quarter is likely to have been boosted by solid segmental performances.

Zacks Equity Research

Here's Why You Should Retain Masimo (MASI) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Masimo (MASI) owing to its focus on patient monitoring.

Zacks Equity Research

Masimo (MASI) Provides FY22 View, Preliminary FY21 Results Solid

by Zacks Equity Research

Masimo's (MASI) solid full-year results likely to have been boosted by strong product sales.

Zacks Equity Research

Here's Why You Should Retain Masimo (MASI) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Masimo (MASI) owing to its focus on patient-monitoring.

Zacks Equity Research

Study Favors Masimo's (MASI) SedLine for Better Patient Outcome

by Zacks Equity Research

Masimo's (MASI) SedLine is expected to aid in the early identification of patients who are at risk of developing POD.

Zacks Equity Research

Masimo's (MASI) Rad-G Clinical Study Trial Outcome Favorable

by Zacks Equity Research

Masimo's (MASI) latest study results demonstrate that Rad-G Pulse Oximeter can help detect pediatric pneumonia.

Zacks Equity Research

Masimo (MASI) Down 1.2% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Masimo (MASI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Masimo (MASI) Reports SedLine's Psi & DSA Parameter Findings

by Zacks Equity Research

The study findings show that monitoring with Masimo (MASI) SedLine Brain Function Monitoring parameters during CEA surgery can reduce the risk of postoperative delirium.

Zacks Equity Research

Abiomed (ABMD) Beats on Q2 Earnings, Lowers FY22 Guidance

by Zacks Equity Research

Abiomed's (ABMD) strength in Impella product revenues drives its Q2 top line.

Zacks Equity Research

Masimo's (MASI) Q3 Earnings Surpass Estimates, '21 View Up

by Zacks Equity Research

Masimo's (MASI) robust product shipments, along with strong sensor sales, drive its Q3 sales.

Zacks Equity Research

Masimo (MASI) Beats Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Masimo (MASI) delivered earnings and revenue surprises of 3.30% and 3.99%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Masimo (MASI) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Masimo (MASI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Masimo's (MASI) EMMA Capnography on Neonates Favored by New Study

by Zacks Equity Research

Masimo's (MASI) EMMA is likely to aid in maintaining an optimal range of PaCO2 in preterm infants undergoing mechanical ventilation in the neonatal intensive care unit.

Zacks Equity Research

Here's Why You Should Retain Masimo (MASI) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Masimo (MASI) owing to its slew of product launches and regulatory approvals.

Debanjana Dey headshot

Cybersecurity Gains Prominence in MedTech: 3 Stocks to Focus on

by Debanjana Dey

Technology-based healthcare stocks like Henry Schein (HSIC), Veeva Systems (VEEV) and BD (BDX) are expected to continue their rally over the next few months.

Zacks Equity Research

Masimo (MASI) Launches SuperSensor, Boosts Product Profile

by Zacks Equity Research

Masimo's (MASI) launch of SuperSensor can help clinicians to continuously monitor patients through one comprehensive, convenient, noninvasive fingertip solution.

Zacks Equity Research

Masimo's (MASI) ORi Favored by New Study For ICU Patients' ETI

by Zacks Equity Research

Masimo's (MASI) ORi is expected to provide early warnings of impending hypoxemia during the ETI procedure, thus aiding in averting any adverse incident.

Zacks Equity Research

Masimo (MASI) Ties Up to Educate on Prescription Opioid Overuse

by Zacks Equity Research

Masimo (MASI) partners with Penington Institute to increase awareness on overdose from prescription opioids.

Zacks Equity Research

Masimo (MASI) Strengthens Global Footprint With New Launch

by Zacks Equity Research

Masimo's (MASI) western Europe launch of SafetyNet Alert not only expands its global presence but also aids in protecting patients taking opioids at home.